Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma

Advanced, late-stage Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) is incurable, and its treatment remains a clinical and therapeutic challenge. Results from a phase II clinical trial in advanced NPC patients employing a combined chemotherapy and EBV-specific T cell (EBVST) immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Richard, Xiang, Wenwei, Marlier, Damien, Au, Veonice Bijin, Ching, Qianting, Wu, Lynn Xue, Guan, Rujun, Lee, Bernett, Chia, Whay-Kuang, Wang, Who-Whong, Wee, Joseph, Ng, Joanna, Cheong, Rachael, Han, Shuting, Chu, Axel, Chee, Chit Lai, Shuen, Timothy, Podinger, Michael, Lezhava, Alexander, Toh, Han Chong, Connolly, John E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854281/
https://www.ncbi.nlm.nih.gov/pubmed/33038324
http://dx.doi.org/10.1016/j.ymthe.2020.09.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854281/
https://www.ncbi.nlm.nih.gov/pubmed/33038324
http://dx.doi.org/10.1016/j.ymthe.2020.09.040

Ejemplares similares